哌拉西林/他唑巴坦治疗小儿先天性巨结肠肠炎的疗效观察

Efficacy Observation of Piperacillin / Tazobactam in the Treatment of Children with Congenital Megacolon Enteritis

目的：评价哌拉西林／他唑巴坦治疗小儿先天性巨结肠肠炎的疗效和安全性。方法：先天性巨结肠肠炎住院患儿122例随机分为两组。观察组72例应用哌拉西林／他唑巴坦钠治疗；对照组50例应用头孢哌酮／舒巴坦钠治疗。两组疗程均为7-14d。比较两组患儿治疗前后C反应蛋白差值、白细胞计数差值和中性粒细胞百分比差值，以及两组平均治疗时间，评价两组临床疗效、细菌清除率和安全性。结果：两组治疗前后c蛋白差值、白细胞计数差值、中性粒细胞百分比差值等比较，差异无统计学意义（P〉0．05）。观察组与对照组有效率分别为86．11％和88．00％（P〉0．05）。全部患儿致病菌阳性率为75．41％，以大肠埃希菌为首位致病菌。观察组细菌清除率为85．96％，高于对照组的80．00％（P〈0．05）。两组患儿均未发生药品不良反应。结论：哌拉西林／他唑巴坦治疗小儿先天性巨结肠肠炎疗效更显，而且未见不良反应。

Objective： To evaluate the curative effect and safety of piperacillin/tazobactam in the treatment of children with con- genital gegacolon enteritis. Methods： 122 cases of congenital intestinal enteritis were randomly divided into two groups. The 72 pa- tients in the treatment group were treated with piperacillin/tazobactam sodium, and the 50 patients in the control group were treated with cefoperazone/sulbactam. The course of treatment was 714 days. The differences in C-reactive proteins, bolld leukocytes count and neutrophilic granulocyte percentage before and after the treatment, and the average treatment time in both groups were compared, and the efficacy and bacterial clearance were evaluated. Results： Between the treatment group and the control group, the differences in C- reactive protein, blood leukocytes count and neutrophilic granulocyte precentage before and after the treatment had no statistical signifi- cance （ P 〉 0.05 ）. The effective rete of the treatment group was 86.11%, and that of the control group was 88 % （ P 〉 0.05 ）. The pos- itive detection rate of pathogenic bacteria was 75.41%, in which Escherichia coli was the first pathogenic bacteria. The bacterial clear- ance in the treatment group was 85.96% , which was higher than that （80%） in the control group（ P 〉 0.05 ）. Conclusion： The effi- cacy of piperacillin/tazobactam in the treatment of children with congenital megacolon enteritis is more obvious with promising safety.